Interní Med. 2009; 11(6)

Diabetologické minimum pro internisty - současné trendy v terapii diabetu 2. typu

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Diabetologické minimum pro internisty - současné trendy v terapii diabetu 2. typu. Interní Med. 2009;11(6):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahmed I, Goldstein BJ. Insulin and endothelial fiction: a brief review. Insulin 2008; 3: 185-188. Go to original source...
    2. Mokáň M, Martinka E, Galajda P, a kol. Diabetes mellitus a vybrané metabolické ochorenia. P+M, Martin 2008: 1003 s.
    3. Nolan CJ, Leahy JL, Delghingaro-Augusto V, et al. Betacell compensation for insulin resistence in Zucker fatty rats: increased lipolysis and fatty acvid signalling. Diabetologia 2006; 49: 2120-2130. Go to original source... Go to PubMed...
    4. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 (Suppl 1): S119-S124. Go to original source... Go to PubMed...
    5. Rybka J. Významné výsledky výzkumu mění stategii farmakoterapie diabetu 2. typu. Medicína po promoci, 2009; 10, 2: 71-79.
    6. Škrha J. Biochemie a patofyziologie. In: Škrha J, et al. Diabetologie. Galén 2009: 33-70.
    7. Unger J. Reducing Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Primary Care Call to Action. Insulin A Clinical Journal for Health Care Professionals 2008: 176-184. Go to original source...
    8. DeFronzo R, Banerji M, Bray G, Buchanan T, Clement S, Henry R, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, Tripathy, D. Reduced Insulin Secretion/Insulin Resistance (Diposition) Index is the Primary Determinant of Glucose Intolerance in the Prediabetic State: results from ACT NOW. 68th Scientific Sessions, Oral Presentation, 151, ADA 2008.
    9. Rybka J. Strategie léčby diabetu 2. typu - 2007. Současná klinická praxe, 2008; 7 (1): 1-8.
    10. Wajchenberg BL. B-Cell Failure in Diabetes and Preservation by Clinical Treatment. Endocr Rev 2007; 28 (2): 187-218. Go to original source... Go to PubMed...
    11. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625. Go to original source... Go to PubMed...
    12. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a, ,causal" antioxidant therapy. Diabetes Care 2003; 26: 1589-1596. Go to original source... Go to PubMed...
    13. Flekač M, Škrha J. Oxidační stres, antioxidační enzymy a úloha paraxonázy 1 v rozvoji diabetické angiopatie. In. Haluzík M. (pořadatel): Trendy soudobé diabetologie 12, Galén, Praha 2008: 155-180.
    14. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. Go to original source... Go to PubMed...
    15. Song SH, Rhodes CJ, Veldhuis JD, Butler PC. Diazoxide attenuates glucose-induced defects in first-phase insulin repase and pulsatile insulin secretion in human islets. Endocrinology 2003; 144: 3399-3405. Go to original source... Go to PubMed...
    16. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of post-prandial hypertriglyceridemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218. Go to original source... Go to PubMed...
    17. Rybka J. Postprandiální hyperglykemie - současná léčba. Causa Subita, 2006; 9 (4): 153-155.
    18. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic kontrol precedens stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30:263-269. Go to original source... Go to PubMed...
    19. Škrha J. Současnost a perspektivy léčby diabetu - patofyziologické poznámky. Předneseno na slavnostním Diabetologickém dni, Pokroky v diabetologii: Zlín 2007.
    20. Corgnali M, Piconi L, Ihnat M, Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic, ,memory" induced by high glucose in isolated human endothelial cells. Diab Metab Res Rev 2008; 24: 301-309. Go to original source... Go to PubMed...
    21. El-Osta A, Brasacchio D, Yao DC, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409-2417. Go to original source... Go to PubMed...
    22. Škrha J. Komentář patofyziologa. Má gliklazid další účinky? In: Perušičová J, Češka R, a kol. Kardiabetes. Kardiovaskulární choroby & diabetes mellitus. Facta Medica, 2009: 207-214.
    23. Sawada F, Inoguchi T, Tsubouchi H, et al. Differential effect of sulphonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. Metabolism 2008; 57: 1038-1045. Go to original source... Go to PubMed...
    24. Škrha J, Prázný M, Hilgertová J, et al. Oxidative stress and endothelium influenced by metformin in Type 2 diabetes mellitus. Eur J Clin Pharmacol 2007; 63: 1107-1114. Go to original source... Go to PubMed...
    25. Weng J, Li Y, Xu W, Shi L. Effect of intensive insulin therapy on beta-cell funtion and glycaemic control in patients with newly diagnosed type 2 diabetes a multicentre randomised parallel-group trial. Lancet 2008; 371 (9626): 1753-1760. Go to original source... Go to PubMed...
    26. Xu L, Man D, Charonnel B, et al. Effect of sitagliptin a dipeptidylpeptidase4 inhibitor on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008; 10 (12): 1212-1220. Go to original source... Go to PubMed...
    27. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensit treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986. Go to original source... Go to PubMed...
    28. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008; 359, 15: 1577-1589. Go to original source... Go to PubMed...
    29. Holman RR, Watkins PJ. UKPDS the first 30 years. WileyBlackwel Publ Ltd, 2008: 175 s.
    30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352, 9131: 854-865. Go to original source...
    31. Raccah D. Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. Diabetes Metab 2006; 32 (2): 48-51. Go to original source... Go to PubMed...
    32. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from Steno-2 study. Diabetes Care 2008; 31 (8): 1510-1515. Go to original source... Go to PubMed...
    33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New Engl J Med 2008; 358: 580-591. Go to original source... Go to PubMed...
    34. Schroeder SA, Tayek JA, Gade P, et al. Multifactorial Intervention and Mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 2292-2293. Go to original source... Go to PubMed...
    35. Ryden L, Standl E, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 2007; 28 (1): 88-136.
    36. Svačina Š, Šmahelová A, Haluzík M. Perorální antidiabetika. In: Škrha J. et al. Diabetologie. Galén 2009: 284-319.
    37. Doporučený postup péče o diabetes mellitus 2. typu. ČDS 2009 - upravená verze.
    38. Nathan DM, et al. Management of Hyperglycemia in Type 2 diabetes. In: White, JR, Campbell RK. ADA/PDR. Medications for the Treatment of Diabetes. ADA 2008: 17-31.
    39. Nathan DM, et al. Management of Hyperglycemia in Type 2 diabetes. A Consensus algorithm White JR, Campbell RK. ADA/PDR. Medications for the Treatment of Diabetes. ADA 2008. 33-37. Go to original source...
    40. Uličianski V. Liečba diabetes mellitus 2. typu. In: Mokáň M, Martinka E, Galajda P, a kol. Diabetes mellitus a vybrané metabolické ochorenia. P+M, Martin 2008: 276-323.
    41. Perušičová J. Prevence a léčba kardiabetu. In: Perušičová J, Češka R. a kol. Kardiabetes. Kardiovaskulární choroby&diabetes mellitus. Facta Medica 2009: 153-207.
    42. Šmahelová A. Význam kombinovaných perorálních antidiabetik v léčbě diabetu 2. typu. Interní Med. 2009; 4 (11): 155-158.
    43. Olšovský J. Jak používat perorální antidiabetika - algoritmy výběru. Farmakoterapie, 2009; 1: 38-44.
    44. Rybka J. Terapie diabetes mellitus. In: Diabetes mellitus - komplikace a přidružená onemocnění. Diagnostické a léčebné postupy. Grada Publishing Praha, 2007: 31-70.
    45. Škrha J. Terapie DM. In: Škrha J, et al. Diabetologie. Galén 2009: 263-268.
    46. Pelikánová T. Inzulin. In: Škrha J, et al. Diabetologie. Galén Praha 2009; 298-321.
    47. Ceriello A, Bortolotti N, Motz E, et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabete: The possible role of hyperglycemia. Metabolism. 1999; 48: 1503-1508. Go to original source... Go to PubMed...
    48. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8: 436-447. Go to original source... Go to PubMed...
    49. Dormandy JA, Charbonnel B, Škrha J, et al. PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAZONE Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
    50. American Diabetes Association: Standards of medical care in diabetes - 2006. Diabetes Care 2006, 29 (Suppl. 1): S4-42. Go to original source... Go to PubMed...
    51. Doležal T. Léčba hyperglykemie u pacientů s diabetem 2. typu: konsensus EASD (European Association for the Study of Diabetes) a ADA (American Diabetes Association). Farmakoterapie 2007; 3 (1): 83-86.
    52. Nathan DM et al. Management of hyperglycemia in Type 2 diabetes mellitus. A consensus algorithm for initiation and adjustment of therapy: A consensus statement from the ADA and EASD. Diabetologia 2006; 49: 1711-1721. Go to original source... Go to PubMed...
    53. Abraira C, et al. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim analysis. Diab Obes Metab 2008. Go to original source...
    54. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
    55. The ADVANCE Collaboration Group: Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
    56. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a konsensus algorithm for the initiation and adjustment of therapy. Diabetologia, 2009; 52 (1): 17. Go to original source... Go to PubMed...
    57. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352, 9131: 837-853. Go to original source...
    58. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. Diabates Care 1999; 22 (1): 99-111. Go to original source... Go to PubMed...
    59. Ihnat MA, Thorpe JE, Kamat CD, et al. Reactive oxygen species mediate a cellular, ,memory" of high glucose signaling. Diabetologia 2007; 50 (7): 1523-1531. Go to original source... Go to PubMed...
    60. Skyler JS, Bergenstal R, O´Bonow R, et al. Intensive glycemic control and the prevention of cardiovascular events: implication of ACCORD, ADVANCE, and VA Diabetes trials. Diabetes Care 2009; 32 (1): 187-192. Go to original source... Go to PubMed...
    61. Kvapil M. Studie ADVANCE v kontextu ostatních morbimortalitních studií u pacientů s diabetem 2. typu, Interní Med. 2008; 10 (12): 583-587.
    62. Kvapil M., ,Nová diabetologie" potřebuje nové léky. Remedia 2008; 18 (6): 440-442.
    63. Škrha J. a výbor diabetologické společnosti. Diabetes mellitus 2002 v České republice - epidemilogická studie DMEV 8, 2005; 1: 5-12.
    64. Škrha J. Komplexní léčba diabetika oproti, ,pouhé" léčbě diabetu. In. Perušičová J, Češka R, a kol. Kardiabetes. Kardiovaskulární choroby & diabetes mellitus. Facta Medica 2009: 211-214.
    65. ##
    66. Šmahelová A. Perorální antidiabetika skupiny derivátů sulfonylurey. Remedia 2008; (Suppl. 1): 56-60.
    67. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning theßcell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268: 423. Go to original source... Go to PubMed...
    68. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 836. Go to original source...
    69. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350: 1838. Go to original source... Go to PubMed...
    70. Babenko AP, Polak M, Cave H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355: 456. Go to original source... Go to PubMed...
    71. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355: 467. Go to original source... Go to PubMed...
    72. Jönsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142. Go to original source... Go to PubMed...
    73. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994; 17: 1026. Go to original source... Go to PubMed...
    74. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751. Go to original source... Go to PubMed...
    75. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467. Go to original source... Go to PubMed...
    76. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681. Go to original source...
    77. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidindiones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabet Care 2008; 31: 173-175. Go to original source... Go to PubMed...
    78. Martin S, Kolb H, Beuth J, et al. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003; 46: 1611-1617. Go to original source... Go to PubMed...
    79. Lebovitz HE. Therapy for Diabetes mellitus and related disorders. Fourth ed. American Diabetes Association, Alexandria, Virginia 2004: 164-175.
    80. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100. Go to original source... Go to PubMed...
    81. Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 12, 2000: 405-412. Go to original source... Go to PubMed...
    82. Shakuto S, Oshima K, Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2005; 182: 209-217. Go to original source... Go to PubMed...
    83. Katakami N, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004; 47: 1906-1913. Go to original source... Go to PubMed...
    84. Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002; 45: 1034-1037. Go to original source... Go to PubMed...
    85. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009; 58: 143-148. Go to original source... Go to PubMed...
    86. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976; 25: 1129. Go to PubMed...
    87. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27:201. Go to original source... Go to PubMed...
    88. Malmberg K. The DIGAMI Study Group. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512. Go to original source... Go to PubMed...
    89. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 169. Go to original source... Go to PubMed...
    90. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119. Go to original source... Go to PubMed...
    91. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 169. Go to original source... Go to PubMed...
    92. Bell DS. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174: 185. Go to original source... Go to PubMed...
    93. Arruda-Olson AM, Patch RK, 3rd, Leibson, CL, et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 2009; 84: 28. Go to original source...
    94. Dranchin N, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005; 21: 143-149. Go to original source... Go to PubMed...
    95. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008; 12, 358 (24): 2545-2559. Go to original source... Go to PubMed...
    96. The Action to Control Cardiovascular Risk in Diabetes Study Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008; 12, 358 (24): 2560-2572. Go to original source... Go to PubMed...
    97. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 38: 2413-2414. Go to original source... Go to PubMed...
    98. ##
    99. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003, 19(7): 635-641. Go to original source... Go to PubMed...
    100. Bell, DSH. Current status of diabetes treatment. South Med J 2002; 95(1): 24-29. Go to original source... Go to PubMed...
    101. Garber AJ. Metformin and other biguanides: Pharmacology and therapeutic usage. In Int Textbook of Diabetes Mellitus, Third Edition, edited by DeFronzo RA, Feranini E, et al. John Wiley&Sons Ltd., 2004: 851-869. Go to original source...
    102. Cusi K, Consoli A, DeFronzo R. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-4067. Go to original source...
    103. Perielo G, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928. Go to original source... Go to PubMed...
    104. Goodarzi MO, Bryer-Ash M. Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agent. Diabetes Obes Metab 2005; 7: 654-662. Go to original source... Go to PubMed...
    105. Ong CR, Molyneaux LM, Constantino MI, et al. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006; 29 (11): 2361-2364. Go to original source... Go to PubMed...
    106. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351. Go to original source... Go to PubMed...
    107. Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulphonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 810-816. Go to original source... Go to PubMed...
    108. Bloomgarden ZT. Diabetes Treatment. Diabetes Care 2009; 32(3): 25-30. Go to original source... Go to PubMed...
    109. McGuiness ME, Telbert RL. Phenformin induced lactic acidosis: a forgotten averse drug reaction. Ann Pharmacother 1993; 27: 1183-1187. Go to original source... Go to PubMed...
    110. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylurea or other antidiabetic drugs and the risk of lactic acidosis or hypoglycemia. A nested case-control analysis. Diabetes Care 2008; 31(11): 2086-2091. Go to original source... Go to PubMed...
    111. Davis SN, Mann S, Briscoe V, et al. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes 2009; 58: 701-709. Go to original source... Go to PubMed...
    112. Perušičová J. Metformin - lék první volby u diabetiků 2. typu. In: Diabetologie 2007: Perorální antidiabetika a jejich postavení v léčbě diabetu mellitu 2. typu. Triton, Praha 2007.
    113. Glueck CJ, Fontaine RN, et al. Metformin reduces weight, centripetal obesity, insulin, leptin and low density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50(7): 856-861. Go to original source... Go to PubMed...
    114. Charles MA, Eschwege E, Grandmottet P, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridemia and central fat distribution: the BIGPRO 1,2 trial. Diabetes Metab Res Rev 2000; 16: 2-7. Go to original source... Go to PubMed...
    115. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179-2187. Go to original source... Go to PubMed...
    116. UK Prospective Diabetes Stud (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998; 358: 854-865. Go to original source...
    117. Kraemer de Aguiar LG, Bahia LR, Villela N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006; 29(5): 1083-1089. Go to original source...
    118. Diabetes Prevention Program Research Group. Role of insulin Secretion and Sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. Effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414. Go to original source... Go to PubMed...
    119. Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572. Go to original source... Go to PubMed...
    120. Diabetes Prevention Program Research group. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention. Diabetes Care 2009; 32(4): 726-732. Go to original source... Go to PubMed...
    121. Tibaldi J. Preserving insulin secretion in Type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2008; 3 (2): 147-159. Go to original source... Go to PubMed...
    122. Marchesini G, Marzocchi R, et al. Non-alcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16(4): 421-427. Go to original source... Go to PubMed...
    123. Cristello F, Cela V, Artin PG, et al. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21(6): 340-352. Go to original source... Go to PubMed...
    124. Yong-Woon K, Jong-Yeon K, Yong-Hoon P, et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistence. Diabetes 2006; 55: 716-724. Go to original source... Go to PubMed...
    125. Paiva M, Riksen NP, Davidson SM. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009 Mar 11 (Epub ahead of print). Go to original source... Go to PubMed...
    126. ##
    127. Finegood DT, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats, rosiglitazon prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029. Go to original source... Go to PubMed...
    128. Lister CA, et al. Rosiglitazone but no metformin or glibenclamid improves glycemic control and increases islet cell content. Diabetologie 1999; 42 (Suppl 1): A150.
    129. Lebovitz HE, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol Metab 2001; 86: 280-288. Go to original source... Go to PubMed...
    130. Jones NP, et al. Diabetologia. 1999; 42 (suppl 1): A 229.
    131. Perušičová J. Desatero léčby perorálními antidiabetiky. Praha Triton 2004.
    132. Weismann P, et al. the EMPIRE Study: Current Medical Research and Opinion. 2005: 21.
    133. American Diabetes Association, Standards of medical care in diabetes. Diabetes Care 2004; 27 (suppl. 1): 15-31. Go to original source... Go to PubMed...
    134. American Association of Clinical Endocrinologists: Medical guidelines for the management of diabetes mellitus. Endocr Pract 2002; 8 (Suppl 1): 40-82. Go to original source... Go to PubMed...
    135. European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabet. Med 1999; 16: 716-730. Go to original source... Go to PubMed...
    136. Rosak C, et al. Rosiglitazon plus metformin is effective and well tolerated in clinical practice, results from large observational studies in people with type 2 diabetes. Int. J. Clin Pract, 2005; 59 (10): 1131-1136. Go to original source... Go to PubMed...
    137. Goldberg R, et al. Pioglitazon versus rosiglitazon u osob s DM 2. typu a dyslipidemií. Diabetes Care 2005; 28: 1547-1554. Go to original source... Go to PubMed...
    138. Takase H, Nakazawa A, Yamashita S, et al. Pioglitazon produces rapid and persistent reduction of vascular inflammation in patiens with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism 2007; 56: 559-564. Go to original source... Go to PubMed...
    139. ##
    140. Nauck MA, et al. Reducet incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52. Go to original source... Go to PubMed...
    141. D'Alessio DA, Vahl TP. Glucagon-like peptid 1: evolution of an incretin into a treatment for diabetes. Am. J. Physiol. Endocrinol. Metab., 2004; 286: E882-E890. Go to original source... Go to PubMed...
    142. Nelson P, et al. The incretin mimetic exenatid as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007; 9: 317-326. Go to original source... Go to PubMed...
    143. Heine RJ, et al. Exenatid versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 2005; 143: 559-569. Go to original source... Go to PubMed...
    144. Davis SN, et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agenst. Diabetes Care 2007; 30: 2972-2973. Go to original source... Go to PubMed...
    145. Kim D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatid on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493. Go to original source... Go to PubMed...
    146. Nauck MA, et al. Five weeks of treatment with the GLP - 1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes. 2006; 114: 417-423. Go to original source... Go to PubMed...
    147. Vilsboli T, et al. Liraglutide, a long-acting human GLP - 1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with 2 diabetes. Diabetes Care 2007; 30: 1608-1610. Go to original source... Go to PubMed...
    148. Feinglos MN, et al. Effects of liraglutide (NN2211), a longacting GLP-1 analogue, on glycemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med, 2005; 22: 1016-1023. Go to original source... Go to PubMed...
    149. Madsbad S, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004; 27: 1335-1342. Go to original source... Go to PubMed...
    150. Nauck MA, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2009; 32: 84-90. Go to original source... Go to PubMed...
    151. Demuth H, et al. Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors. Biochemica and Biophysica Acta 2005; 1751: 33-44. Go to original source... Go to PubMed...
    152. Raz I, et al. Efficacy and safety of the dipeptidyl-peptidase 4 inhibitor sitagliptin as monotherapy in patients with Type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571. Go to original source... Go to PubMed...
    153. Aschner P, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 2006; 29: 2632-2637. Go to original source... Go to PubMed...
    154. Rosensotck J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes; a 24-week, multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 2006; 28: 1556-1568. Go to original source... Go to PubMed...
    155. Charbonnel B, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643. Go to original source... Go to PubMed...
    156. Goldstaein BJ, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patiens with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987. Go to original source... Go to PubMed...
    157. Nauck MA, et al. Efficacy and safety of the dipeptidylpeptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone. A randomized, double-blind, non-inferiority trial. Diab Obes Metab 2007; 9: 194-205. Go to original source... Go to PubMed...
    158. Hermansen K, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab, 2007; 9: 733-745. Go to original source... Go to PubMed...
    159. Dejager S, et al. Vildagliptin in drug-naive patients with Type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res., 2007; 39: 218-223. Go to original source... Go to PubMed...
    160. Pi-Sunyer, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with Type 2 diabetes. Diabetes. Res. Clin. Pract. 2007; 76: 132-138. Go to original source... Go to PubMed...
    161. Bosi E, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with Type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895. Go to original source... Go to PubMed...
    162. Rosenstock J, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with Type 2 diabetes. Diabetes care 2007; 30: 217-223. Go to original source... Go to PubMed...
    163. Kvapil M, Perušičová J. Postprandiální glykemie. Triton, Praha; 2006.
    164. ##
    165. Svačina Š, a kol. Metabolický syndrom. Triton, Praha, 2006.
    166. Svačina Š. Prevence diabetu a jeho komplikací. Triton, Praha, 2008.
    167. Fried M. Moderní chirurgické metody léčby obezity. Grada Publishing, Praha, 2005.
    168. Pitombo C, Jones K, Higa K, Pareja JC. Obezity Surgery: Principles and Praktice. McGraw-Hill Professional, New York, 2007.
    169. Svačina Š. Mortalitní studie v obezitologii. Medicína po promoci 2007; 8 (3): 82-85.
    170. Maggioni A, et al. Safety profile of sibutramine during a six week treatment period in high risk patiens - an analysis of SCOUT Study, Int. J. Obez. 2007, 31 (Suppl. 1): 167.
    171. Arterbum D, et al. Efficacy and safety of sibutramine for weight loss. A systematic review. Ann Intern Med. 2004; 164: 994-1003. Go to original source... Go to PubMed...
    172. Sharma AM, et al. Moxonidine in the treatment of overweight obeze patiens with metabolic syndrome: a postmarketing surveillance study. J of Human Hyper. 2004; 18: 669-675. Go to original source... Go to PubMed...
    173. Svačina Š, Owen K, Hendl J, Matoulek M, Brychta T. Comparison of Lipid Lowering Effect of Sibutramine in Patients Treated or not Treated with Statins - 3 month Follow-up Prague Medical report Vol 2007; 108 (4): 333-338. Go to PubMed...
    174. Wadden TA, et al. Randomized trial of lifestyle modification and pharmacotherapy for obezity. N Engl J Med. 2005; 353: 2111-2120. Go to original source... Go to PubMed...
    175. James WPT, et al. Effect of sibutramine on weight meitenance after weight loss. Lancet 2000; 356: 2119-2125. Go to original source... Go to PubMed...
    176. Šmahelová A. Výsledky multicentrického sledování léčby sibutraminem u obézních diabetiků v České republice. Vnitřní lékařství, 2005; 6: 676-680.
    177. Coletta DK, et al. The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data. Diab Vasc Dis Res. 2006; 3 (3): 186. Go to original source... Go to PubMed...
    178. Kopelman P, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obeze patients. Int J Obez (Lond). 2007; 31 (3): 494-499. Go to original source... Go to PubMed...
    179. Bayes HF. Current and investigational antiobezity agents and obezity therapeutic treatment targets. Obez Res. 2004; 12 (8): 1197-1211. Go to original source... Go to PubMed...
    180. Kvasnička T. Endokanabinoidy - nová volba v léčbě metabolického synromu a zástavě kouření. Cas Lek Cesk. 2005; 144: 81-84. Go to PubMed...
    181. Takahiro T, et al. Glimepiride increases HDL cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metab Clin nad Experim 2009; 58: 143-148. Go to original source... Go to PubMed...
    182. Svačina Š, Doležal T. Exenatid. Farmakoterapie 2008; 3, 291-295.
    183. Šmahelová A. Liraglutid. Farmakoterapie 2008; 3: 260-264.
    184. Svačina Š. Potenciální nová antidiabetika v příštím desetiletí. Vnitřní lékařství, 2009; 4: v tisku.
    185. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes) -2 study. Diabetes Care 2009; 32 (1): 84-90. Go to original source... Go to PubMed...
    186. Bhushan, et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract. 2008; 14 (8): 993-999. Go to original source... Go to PubMed...
    187. ##
    188. Jects With Poorly Controlled Type 2 Diabetes. Diabetes Care, 2005; 28: 1282-1288.
    189. Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine, 2008; 359: 1-13. Go to original source... Go to PubMed...
    190. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352: 837-835. Go to original source...
    191. Brunton S, et al. Type 2 diabetes: the role of insulin. J. Fam. Pract. 2005; 54 (5 suppl.): 445-451.
    192. Adamíková A. Vliv inzulinoterapie na přírůstky hmotnosti. Medical Tribune, 2008; 4 (10): 13.
    193. Svačina Š. Význam struktury inzulinových přípravků pro klinickou praxi. Vnitřní lékařství, 2009; 55 (4): 409-411. Go to PubMed...
    194. Pelikánová T. Léčba inzulinem v éře inzulinových analog. In. Pelikánová T, a kol. Trendy soudobé diabetologie. Svazek 11, s. 181-243. Praha: Galén, 2007.
    195. Perušičová J. Diabetes mellitus 2. typu. In. Perušičová J, a kol. Co je nového na cestě od diabezity po kardiabetes. Praha: Geum, 2006: 95-113.
    196. Hirsch IB, et al. Insulin Analogues. The New England Journal of Medicine, 2005; 352: 174-183. Go to original source... Go to PubMed...
    197. Cooppan R. Initiating Insulin Therapy in Patients with Type 2 Diabetes: A practical approach. The Internet Journal of Internal Medicine. 2007; 6 (2). Go to original source...
    198. Kvapil M, Adamíková A, Anděl M, Olšovský J, Pelikánová T, Račická E, Rušavý Z. Konsensus k léčbě inzulinovými analogy. DMEV, 2008; 11 (3): 1-7.
    199. Adamíková A. Inzulin glargin a lepší glykemická kontrola u diabetiků 2. typu-studie TULIP. Komentář. Farmakoterapie, 2009; 5 (1): 13-15.
    200. Blicklé JF, Hancu M, Piletic M, et al. Insulin glargine provides greater improvements in glycemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8 % A1c levels. The TULIP study. Diabetes, Obesity and Metabolism, 2008, publish online, Dec. 14, Blackwell Publishing Ltd. Go to original source...
    201. Garber AJ, et al. Premixed Insulin Analogues for the Treatment of Diabetes Mellitus. Drugs 2006; 66 (1): 31-49. Go to original source... Go to PubMed...
    202. Meneghini L, Koenen C, Weng W, Selam JL. PREDICTIVE 303 Study: Implementation and outcomes of a simplified self-titration dosing guideline for insulin detemir in patients with type 2 diabetes. Abstract Volume 43rd Annual Meeting, Amsterdam, 2007: S 98.
    203. Rosenstock J, et al. A randomized, 52-week, treat-totarget trial comparing insulin detemir with insulin glargin when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416. Go to original source... Go to PubMed...
    204. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine, 2008; 358: 2545-2559. Go to original source... Go to PubMed...
    205. Ahmed I, Goldstein BJ. Insulin and endothelial fiction: a brief review. Insulin 2008; 3: 185-188. Go to original source...
    206. Mokáň M, Martinka E, Galajda P, a kol. Diabetes mellitus a vybrané metabolické ochorenia. P+M, Martin 2008: 1003 s.
    207. Nolan CJ, Leahy JL, Delghingaro-Augusto V, et al. Betacell compensation for insulin resistence in Zucker fatty rats: increased lipolysis and fatty acvid signalling. Diabetologia 2006; 49: 2120-2130. Go to original source... Go to PubMed...
    208. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 (Suppl 1): S119-S124. Go to original source... Go to PubMed...
    209. Rybka J. Významné výsledky výzkumu mění stategii farmakoterapie diabetu 2. typu. Medicína po promoci, 2009; 10, 2: 71-79.
    210. Škrha J. Biochemie a patofyziologie. In: Škrha J, et al. Diabetologie. Galén 2009: 33-70.
    211. Unger J. Reducing Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Primary Care Call to Action. Insulin A Clinical Journal for Health Care Professionals 2008: 176-184. Go to original source...
    212. DeFronzo R, Banerji M, Bray G, Buchanan T, Clement S, Henry R, Kitabchi A, Mudaliar S, Musi N, Ratner R, Reaven P, Schwenke D, Tripathy, D. Reduced Insulin Secretion/Insulin Resistance (Diposition) Index is the Primary Determinant of Glucose Intolerance in the Prediabetic State: results from ACT NOW. 68th Scientific Sessions, Oral Presentation, 151, ADA 2008.
    213. Rybka J. Strategie léčby diabetu 2. typu - 2007. Současná klinická praxe, 2008; 7 (1): 1-8.
    214. Wajchenberg BL. B-Cell Failure in Diabetes and Preservation by Clinical Treatment. Endocr Rev 2007; 28 (2): 187-218. Go to original source... Go to PubMed...
    215. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625. Go to original source... Go to PubMed...
    216. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a, ,causal" antioxidant therapy. Diabetes Care 2003; 26: 1589-1596. Go to original source... Go to PubMed...
    217. Flekač M, Škrha J. Oxidační stres, antioxidační enzymy a úloha paraxonázy 1 v rozvoji diabetické angiopatie. In. Haluzík M. (pořadatel): Trendy soudobé diabetologie 12, Galén, Praha 2008: 155-180.
    218. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. Go to original source... Go to PubMed...
    219. Song SH, Rhodes CJ, Veldhuis JD, Butler PC. Diazoxide attenuates glucose-induced defects in first-phase insulin repase and pulsatile insulin secretion in human islets. Endocrinology 2003; 144: 3399-3405. Go to original source... Go to PubMed...
    220. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of post-prandial hypertriglyceridemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218. Go to original source... Go to PubMed...
    221. Rybka J. Postprandiální hyperglykemie - současná léčba. Causa Subita, 2006; 9 (4): 153-155.
    222. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic kontrol precedens stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30:263-269. Go to original source... Go to PubMed...
    223. Škrha J. Současnost a perspektivy léčby diabetu - patofyziologické poznámky. Předneseno na slavnostním Diabetologickém dni, Pokroky v diabetologii: Zlín 2007.
    224. Corgnali M, Piconi L, Ihnat M, Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic, ,memory" induced by high glucose in isolated human endothelial cells. Diab Metab Res Rev 2008; 24: 301-309. Go to original source... Go to PubMed...
    225. El-Osta A, Brasacchio D, Yao DC, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409-2417. Go to original source... Go to PubMed...
    226. Škrha J. Komentář patofyziologa. Má gliklazid další účinky? In: Perušičová J, Češka R, a kol. Kardiabetes. Kardiovaskulární choroby & diabetes mellitus. Facta Medica, 2009: 207-214.
    227. Sawada F, Inoguchi T, Tsubouchi H, et al. Differential effect of sulphonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. Metabolism 2008; 57: 1038-1045. Go to original source... Go to PubMed...
    228. Škrha J, Prázný M, Hilgertová J, et al. Oxidative stress and endothelium influenced by metformin in Type 2 diabetes mellitus. Eur J Clin Pharmacol 2007; 63: 1107-1114. Go to original source... Go to PubMed...
    229. Weng J, Li Y, Xu W, Shi L. Effect of intensive insulin therapy on beta-cell funtion and glycaemic control in patients with newly diagnosed type 2 diabetes a multicentre randomised parallel-group trial. Lancet 2008; 371 (9626): 1753-1760. Go to original source... Go to PubMed...
    230. Xu L, Man D, Charonnel B, et al. Effect of sitagliptin a dipeptidylpeptidase4 inhibitor on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008; 10 (12): 1212-1220. Go to original source... Go to PubMed...
    231. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensit treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986. Go to original source... Go to PubMed...
    232. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008; 359, 15: 1577-1589. Go to original source... Go to PubMed...
    233. Holman RR, Watkins PJ. UKPDS the first 30 years. WileyBlackwel Publ Ltd, 2008: 175 s.
    234. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352, 9131: 854-865. Go to original source...
    235. Raccah D. Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. Diabetes Metab 2006; 32 (2): 48-51. Go to original source... Go to PubMed...
    236. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from Steno-2 study. Diabetes Care 2008; 31 (8): 1510-1515. Go to original source... Go to PubMed...
    237. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New Engl J Med 2008; 358: 580-591. Go to original source... Go to PubMed...
    238. Schroeder SA, Tayek JA, Gade P, et al. Multifactorial Intervention and Mortality in Type 2 Diabetes. N Engl J Med 2008; 358: 2292-2293. Go to original source... Go to PubMed...
    239. Ryden L, Standl E, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 2007; 28 (1): 88-136.
    240. Svačina Š, Šmahelová A, Haluzík M. Perorální antidiabetika. In: Škrha J. et al. Diabetologie. Galén 2009: 284-319.
    241. Doporučený postup péče o diabetes mellitus 2. typu. ČDS 2009 - upravená verze.
    242. Nathan DM, et al. Management of Hyperglycemia in Type 2 diabetes. In: White, JR, Campbell RK. ADA/PDR. Medications for the Treatment of Diabetes. ADA 2008: 17-31.
    243. Nathan DM, et al. Management of Hyperglycemia in Type 2 diabetes. A Consensus algorithm White JR, Campbell RK. ADA/PDR. Medications for the Treatment of Diabetes. ADA 2008. 33-37. Go to original source...
    244. Uličianski V. Liečba diabetes mellitus 2. typu. In: Mokáň M, Martinka E, Galajda P, a kol. Diabetes mellitus a vybrané metabolické ochorenia. P+M, Martin 2008: 276-323.
    245. Perušičová J. Prevence a léčba kardiabetu. In: Perušičová J, Češka R. a kol. Kardiabetes. Kardiovaskulární choroby&diabetes mellitus. Facta Medica 2009: 153-207.
    246. Šmahelová A. Význam kombinovaných perorálních antidiabetik v léčbě diabetu 2. typu. Interní Med. 2009; 4 (11): 155-158.
    247. Olšovský J. Jak používat perorální antidiabetika - algoritmy výběru. Farmakoterapie, 2009; 1: 38-44.
    248. Rybka J. Terapie diabetes mellitus. In: Diabetes mellitus - komplikace a přidružená onemocnění. Diagnostické a léčebné postupy. Grada Publishing Praha, 2007: 31-70.
    249. Škrha J. Terapie DM. In: Škrha J, et al. Diabetologie. Galén 2009: 263-268.
    250. Pelikánová T. Inzulin. In: Škrha J, et al. Diabetologie. Galén Praha 2009; 298-321.
    251. Ceriello A, Bortolotti N, Motz E, et al. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabete: The possible role of hyperglycemia. Metabolism. 1999; 48: 1503-1508. Go to original source... Go to PubMed...
    252. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006; 8: 436-447. Go to original source... Go to PubMed...
    253. Dormandy JA, Charbonnel B, Škrha J, et al. PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAZONE Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289. Go to original source... Go to PubMed...
    254. American Diabetes Association: Standards of medical care in diabetes - 2006. Diabetes Care 2006, 29 (Suppl. 1): S4-42. Go to original source... Go to PubMed...
    255. Doležal T. Léčba hyperglykemie u pacientů s diabetem 2. typu: konsensus EASD (European Association for the Study of Diabetes) a ADA (American Diabetes Association). Farmakoterapie 2007; 3 (1): 83-86.
    256. Nathan DM et al. Management of hyperglycemia in Type 2 diabetes mellitus. A consensus algorithm for initiation and adjustment of therapy: A consensus statement from the ADA and EASD. Diabetologia 2006; 49: 1711-1721. Go to original source... Go to PubMed...
    257. Abraira C, et al. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim analysis. Diab Obes Metab 2008. Go to original source...
    258. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. Go to original source... Go to PubMed...
    259. The ADVANCE Collaboration Group: Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
    260. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a konsensus algorithm for the initiation and adjustment of therapy. Diabetologia, 2009; 52 (1): 17. Go to original source... Go to PubMed...
    261. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352, 9131: 837-853. Go to original source...
    262. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial Cohort. Diabates Care 1999; 22 (1): 99-111. Go to original source... Go to PubMed...
    263. Ihnat MA, Thorpe JE, Kamat CD, et al. Reactive oxygen species mediate a cellular, ,memory" of high glucose signaling. Diabetologia 2007; 50 (7): 1523-1531. Go to original source... Go to PubMed...
    264. Skyler JS, Bergenstal R, O´Bonow R, et al. Intensive glycemic control and the prevention of cardiovascular events: implication of ACCORD, ADVANCE, and VA Diabetes trials. Diabetes Care 2009; 32 (1): 187-192. Go to original source... Go to PubMed...
    265. Kvapil M. Studie ADVANCE v kontextu ostatních morbimortalitních studií u pacientů s diabetem 2. typu, Interní Med. 2008; 10 (12): 583-587.
    266. Kvapil M., ,Nová diabetologie" potřebuje nové léky. Remedia 2008; 18 (6): 440-442.
    267. Škrha J. a výbor diabetologické společnosti. Diabetes mellitus 2002 v České republice - epidemilogická studie DMEV 8, 2005; 1: 5-12.
    268. Škrha J. Komplexní léčba diabetika oproti, ,pouhé" léčbě diabetu. In. Perušičová J, Češka R, a kol. Kardiabetes. Kardiovaskulární choroby & diabetes mellitus. Facta Medica 2009: 211-214.
    269. ##
    270. Šmahelová A. Perorální antidiabetika skupiny derivátů sulfonylurey. Remedia 2008; (Suppl. 1): 56-60.
    271. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning theßcell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268: 423. Go to original source... Go to PubMed...
    272. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 836. Go to original source...
    273. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350: 1838. Go to original source... Go to PubMed...
    274. Babenko AP, Polak M, Cave H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355: 456. Go to original source... Go to PubMed...
    275. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355: 467. Go to original source... Go to PubMed...
    276. Jönsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142. Go to original source... Go to PubMed...
    277. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994; 17: 1026. Go to original source... Go to PubMed...
    278. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751. Go to original source... Go to PubMed...
    279. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467. Go to original source... Go to PubMed...
    280. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681. Go to original source...
    281. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidindiones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabet Care 2008; 31: 173-175. Go to original source... Go to PubMed...
    282. Martin S, Kolb H, Beuth J, et al. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003; 46: 1611-1617. Go to original source... Go to PubMed...
    283. Lebovitz HE. Therapy for Diabetes mellitus and related disorders. Fourth ed. American Diabetes Association, Alexandria, Virginia 2004: 164-175.
    284. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100. Go to original source... Go to PubMed...
    285. Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 12, 2000: 405-412. Go to original source... Go to PubMed...
    286. Shakuto S, Oshima K, Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2005; 182: 209-217. Go to original source... Go to PubMed...
    287. Katakami N, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004; 47: 1906-1913. Go to original source... Go to PubMed...
    288. Siluk D, Kaliszan R, Haber P, Petrusewicz J, Brzozowski Z, Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia 2002; 45: 1034-1037. Go to original source... Go to PubMed...
    289. Araki T, Emoto M, Konishi T, et al. Glimepiride increases high-density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism. 2009; 58: 143-148. Go to original source... Go to PubMed...
    290. A study of the effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976; 25: 1129. Go to PubMed...
    291. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27:201. Go to original source... Go to PubMed...
    292. Malmberg K. The DIGAMI Study Group. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512. Go to original source... Go to PubMed...
    293. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 169. Go to original source... Go to PubMed...
    294. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119. Go to original source... Go to PubMed...
    295. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174: 169. Go to original source... Go to PubMed...
    296. Bell DS. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174: 185. Go to original source... Go to PubMed...
    297. Arruda-Olson AM, Patch RK, 3rd, Leibson, CL, et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 2009; 84: 28. Go to original source...
    298. Dranchin N, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005; 21: 143-149. Go to original source... Go to PubMed...
    299. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008; 12, 358 (24): 2545-2559. Go to original source... Go to PubMed...
    300. The Action to Control Cardiovascular Risk in Diabetes Study Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2008; 12, 358 (24): 2560-2572. Go to original source... Go to PubMed...
    301. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 38: 2413-2414. Go to original source... Go to PubMed...
    302. ##
    303. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003, 19(7): 635-641. Go to original source... Go to PubMed...
    304. Bell, DSH. Current status of diabetes treatment. South Med J 2002; 95(1): 24-29. Go to original source... Go to PubMed...
    305. Garber AJ. Metformin and other biguanides: Pharmacology and therapeutic usage. In Int Textbook of Diabetes Mellitus, Third Edition, edited by DeFronzo RA, Feranini E, et al. John Wiley&Sons Ltd., 2004: 851-869. Go to original source...
    306. Cusi K, Consoli A, DeFronzo R. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-4067. Go to original source...
    307. Perielo G, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928. Go to original source... Go to PubMed...
    308. Goodarzi MO, Bryer-Ash M. Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agent. Diabetes Obes Metab 2005; 7: 654-662. Go to original source... Go to PubMed...
    309. Ong CR, Molyneaux LM, Constantino MI, et al. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006; 29 (11): 2361-2364. Go to original source... Go to PubMed...
    310. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351. Go to original source... Go to PubMed...
    311. Eurich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulphonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 810-816. Go to original source... Go to PubMed...
    312. Bloomgarden ZT. Diabetes Treatment. Diabetes Care 2009; 32(3): 25-30. Go to original source... Go to PubMed...
    313. McGuiness ME, Telbert RL. Phenformin induced lactic acidosis: a forgotten averse drug reaction. Ann Pharmacother 1993; 27: 1183-1187. Go to original source... Go to PubMed...
    314. Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylurea or other antidiabetic drugs and the risk of lactic acidosis or hypoglycemia. A nested case-control analysis. Diabetes Care 2008; 31(11): 2086-2091. Go to original source... Go to PubMed...
    315. Davis SN, Mann S, Briscoe V, et al. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes 2009; 58: 701-709. Go to original source... Go to PubMed...
    316. Perušičová J. Metformin - lék první volby u diabetiků 2. typu. In: Diabetologie 2007: Perorální antidiabetika a jejich postavení v léčbě diabetu mellitu 2. typu. Triton, Praha 2007.
    317. Glueck CJ, Fontaine RN, et al. Metformin reduces weight, centripetal obesity, insulin, leptin and low density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50(7): 856-861. Go to original source... Go to PubMed...
    318. Charles MA, Eschwege E, Grandmottet P, et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridemia and central fat distribution: the BIGPRO 1,2 trial. Diabetes Metab Res Rev 2000; 16: 2-7. Go to original source... Go to PubMed...
    319. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179-2187. Go to original source... Go to PubMed...
    320. UK Prospective Diabetes Stud (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998; 358: 854-865. Go to original source...
    321. Kraemer de Aguiar LG, Bahia LR, Villela N, et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006; 29(5): 1083-1089. Go to original source...
    322. Diabetes Prevention Program Research Group. Role of insulin Secretion and Sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. Effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414. Go to original source... Go to PubMed...
    323. Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572. Go to original source... Go to PubMed...
    324. Diabetes Prevention Program Research group. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention. Diabetes Care 2009; 32(4): 726-732. Go to original source... Go to PubMed...
    325. Tibaldi J. Preserving insulin secretion in Type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2008; 3 (2): 147-159. Go to original source... Go to PubMed...
    326. Marchesini G, Marzocchi R, et al. Non-alcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16(4): 421-427. Go to original source... Go to PubMed...
    327. Cristello F, Cela V, Artin PG, et al. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol 2005; 21(6): 340-352. Go to original source... Go to PubMed...
    328. Yong-Woon K, Jong-Yeon K, Yong-Hoon P, et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistence. Diabetes 2006; 55: 716-724. Go to original source... Go to PubMed...
    329. Paiva M, Riksen NP, Davidson SM. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009 Mar 11 (Epub ahead of print). Go to original source... Go to PubMed...
    330. ##
    331. Finegood DT, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats, rosiglitazon prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029. Go to original source... Go to PubMed...
    332. Lister CA, et al. Rosiglitazone but no metformin or glibenclamid improves glycemic control and increases islet cell content. Diabetologie 1999; 42 (Suppl 1): A150.
    333. Lebovitz HE, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol Metab 2001; 86: 280-288. Go to original source... Go to PubMed...
    334. Jones NP, et al. Diabetologia. 1999; 42 (suppl 1): A 229.
    335. Perušičová J. Desatero léčby perorálními antidiabetiky. Praha Triton 2004.
    336. Weismann P, et al. the EMPIRE Study: Current Medical Research and Opinion. 2005: 21.
    337. American Diabetes Association, Standards of medical care in diabetes. Diabetes Care 2004; 27 (suppl. 1): 15-31. Go to original source... Go to PubMed...
    338. American Association of Clinical Endocrinologists: Medical guidelines for the management of diabetes mellitus. Endocr Pract 2002; 8 (Suppl 1): 40-82. Go to original source... Go to PubMed...
    339. European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabet. Med 1999; 16: 716-730. Go to original source... Go to PubMed...
    340. Rosak C, et al. Rosiglitazon plus metformin is effective and well tolerated in clinical practice, results from large observational studies in people with type 2 diabetes. Int. J. Clin Pract, 2005; 59 (10): 1131-1136. Go to original source... Go to PubMed...
    341. Goldberg R, et al. Pioglitazon versus rosiglitazon u osob s DM 2. typu a dyslipidemií. Diabetes Care 2005; 28: 1547-1554. Go to original source... Go to PubMed...
    342. Takase H, Nakazawa A, Yamashita S, et al. Pioglitazon produces rapid and persistent reduction of vascular inflammation in patiens with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism 2007; 56: 559-564. Go to original source... Go to PubMed...
    343. ##
    344. Nauck MA, et al. Reducet incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52. Go to original source... Go to PubMed...
    345. D'Alessio DA, Vahl TP. Glucagon-like peptid 1: evolution of an incretin into a treatment for diabetes. Am. J. Physiol. Endocrinol. Metab., 2004; 286: E882-E890. Go to original source... Go to PubMed...
    346. Nelson P, et al. The incretin mimetic exenatid as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007; 9: 317-326. Go to original source... Go to PubMed...
    347. Heine RJ, et al. Exenatid versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 2005; 143: 559-569. Go to original source... Go to PubMed...
    348. Davis SN, et al. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agenst. Diabetes Care 2007; 30: 2972-2973. Go to original source... Go to PubMed...
    349. Kim D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatid on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493. Go to original source... Go to PubMed...
    350. Nauck MA, et al. Five weeks of treatment with the GLP - 1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes. 2006; 114: 417-423. Go to original source... Go to PubMed...
    351. Vilsboli T, et al. Liraglutide, a long-acting human GLP - 1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with 2 diabetes. Diabetes Care 2007; 30: 1608-1610. Go to original source... Go to PubMed...
    352. Feinglos MN, et al. Effects of liraglutide (NN2211), a longacting GLP-1 analogue, on glycemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med, 2005; 22: 1016-1023. Go to original source... Go to PubMed...
    353. Madsbad S, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004; 27: 1335-1342. Go to original source... Go to PubMed...
    354. Nauck MA, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2009; 32: 84-90. Go to original source... Go to PubMed...
    355. Demuth H, et al. Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors. Biochemica and Biophysica Acta 2005; 1751: 33-44. Go to original source... Go to PubMed...
    356. Raz I, et al. Efficacy and safety of the dipeptidyl-peptidase 4 inhibitor sitagliptin as monotherapy in patients with Type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571. Go to original source... Go to PubMed...
    357. Aschner P, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 2006; 29: 2632-2637. Go to original source... Go to PubMed...
    358. Rosensotck J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes; a 24-week, multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 2006; 28: 1556-1568. Go to original source... Go to PubMed...
    359. Charbonnel B, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with Type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643. Go to original source... Go to PubMed...
    360. Goldstaein BJ, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patiens with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987. Go to original source... Go to PubMed...
    361. Nauck MA, et al. Efficacy and safety of the dipeptidylpeptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone. A randomized, double-blind, non-inferiority trial. Diab Obes Metab 2007; 9: 194-205. Go to original source... Go to PubMed...
    362. Hermansen K, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab, 2007; 9: 733-745. Go to original source... Go to PubMed...
    363. Dejager S, et al. Vildagliptin in drug-naive patients with Type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res., 2007; 39: 218-223. Go to original source... Go to PubMed...
    364. Pi-Sunyer, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with Type 2 diabetes. Diabetes. Res. Clin. Pract. 2007; 76: 132-138. Go to original source... Go to PubMed...
    365. Bosi E, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with Type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895. Go to original source... Go to PubMed...
    366. Rosenstock J, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with Type 2 diabetes. Diabetes care 2007; 30: 217-223. Go to original source... Go to PubMed...
    367. Kvapil M, Perušičová J. Postprandiální glykemie. Triton, Praha; 2006.
    368. ##
    369. Svačina Š, a kol. Metabolický syndrom. Triton, Praha, 2006.
    370. Svačina Š. Prevence diabetu a jeho komplikací. Triton, Praha, 2008.
    371. Fried M. Moderní chirurgické metody léčby obezity. Grada Publishing, Praha, 2005.
    372. Pitombo C, Jones K, Higa K, Pareja JC. Obezity Surgery: Principles and Praktice. McGraw-Hill Professional, New York, 2007.
    373. Svačina Š. Mortalitní studie v obezitologii. Medicína po promoci 2007; 8 (3): 82-85.
    374. Maggioni A, et al. Safety profile of sibutramine during a six week treatment period in high risk patiens - an analysis of SCOUT Study, Int. J. Obez. 2007, 31 (Suppl. 1): 167.
    375. Arterbum D, et al. Efficacy and safety of sibutramine for weight loss. A systematic review. Ann Intern Med. 2004; 164: 994-1003. Go to original source... Go to PubMed...
    376. Sharma AM, et al. Moxonidine in the treatment of overweight obeze patiens with metabolic syndrome: a postmarketing surveillance study. J of Human Hyper. 2004; 18: 669-675. Go to original source... Go to PubMed...
    377. Svačina Š, Owen K, Hendl J, Matoulek M, Brychta T. Comparison of Lipid Lowering Effect of Sibutramine in Patients Treated or not Treated with Statins - 3 month Follow-up Prague Medical report Vol 2007; 108 (4): 333-338. Go to PubMed...
    378. Wadden TA, et al. Randomized trial of lifestyle modification and pharmacotherapy for obezity. N Engl J Med. 2005; 353: 2111-2120. Go to original source... Go to PubMed...
    379. James WPT, et al. Effect of sibutramine on weight meitenance after weight loss. Lancet 2000; 356: 2119-2125. Go to original source... Go to PubMed...
    380. Šmahelová A. Výsledky multicentrického sledování léčby sibutraminem u obézních diabetiků v České republice. Vnitřní lékařství, 2005; 6: 676-680.
    381. Coletta DK, et al. The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data. Diab Vasc Dis Res. 2006; 3 (3): 186. Go to original source... Go to PubMed...
    382. Kopelman P, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obeze patients. Int J Obez (Lond). 2007; 31 (3): 494-499. Go to original source... Go to PubMed...
    383. Bayes HF. Current and investigational antiobezity agents and obezity therapeutic treatment targets. Obez Res. 2004; 12 (8): 1197-1211. Go to original source... Go to PubMed...
    384. Kvasnička T. Endokanabinoidy - nová volba v léčbě metabolického synromu a zástavě kouření. Cas Lek Cesk. 2005; 144: 81-84. Go to PubMed...
    385. Takahiro T, et al. Glimepiride increases HDL cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metab Clin nad Experim 2009; 58: 143-148. Go to original source... Go to PubMed...
    386. Svačina Š, Doležal T. Exenatid. Farmakoterapie 2008; 3, 291-295.
    387. Šmahelová A. Liraglutid. Farmakoterapie 2008; 3: 260-264.
    388. Svačina Š. Potenciální nová antidiabetika v příštím desetiletí. Vnitřní lékařství, 2009; 4: v tisku.
    389. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes) -2 study. Diabetes Care 2009; 32 (1): 84-90. Go to original source... Go to PubMed...
    390. Bhushan, et al. Exenatide use in the management of metabolic syndrome: a retrospective database study. Endocr Pract. 2008; 14 (8): 993-999. Go to original source... Go to PubMed...
    391. ##
    392. Jects With Poorly Controlled Type 2 Diabetes. Diabetes Care, 2005; 28: 1282-1288.
    393. Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine, 2008; 359: 1-13. Go to original source... Go to PubMed...
    394. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352: 837-835. Go to original source...
    395. Brunton S, et al. Type 2 diabetes: the role of insulin. J. Fam. Pract. 2005; 54 (5 suppl.): 445-451.
    396. Adamíková A. Vliv inzulinoterapie na přírůstky hmotnosti. Medical Tribune, 2008; 4 (10): 13.
    397. Svačina Š. Význam struktury inzulinových přípravků pro klinickou praxi. Vnitřní lékařství, 2009; 55 (4): 409-411. Go to PubMed...
    398. Pelikánová T. Léčba inzulinem v éře inzulinových analog. In. Pelikánová T, a kol. Trendy soudobé diabetologie. Svazek 11, s. 181-243. Praha: Galén, 2007.
    399. Perušičová J. Diabetes mellitus 2. typu. In. Perušičová J, a kol. Co je nového na cestě od diabezity po kardiabetes. Praha: Geum, 2006: 95-113.
    400. Hirsch IB, et al. Insulin Analogues. The New England Journal of Medicine, 2005; 352: 174-183. Go to original source... Go to PubMed...
    401. Cooppan R. Initiating Insulin Therapy in Patients with Type 2 Diabetes: A practical approach. The Internet Journal of Internal Medicine. 2007; 6 (2). Go to original source...
    402. Kvapil M, Adamíková A, Anděl M, Olšovský J, Pelikánová T, Račická E, Rušavý Z. Konsensus k léčbě inzulinovými analogy. DMEV, 2008; 11 (3): 1-7.
    403. Adamíková A. Inzulin glargin a lepší glykemická kontrola u diabetiků 2. typu-studie TULIP. Komentář. Farmakoterapie, 2009; 5 (1): 13-15.
    404. Blicklé JF, Hancu M, Piletic M, et al. Insulin glargine provides greater improvements in glycemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8 % A1c levels. The TULIP study. Diabetes, Obesity and Metabolism, 2008, publish online, Dec. 14, Blackwell Publishing Ltd. Go to original source...
    405. Garber AJ, et al. Premixed Insulin Analogues for the Treatment of Diabetes Mellitus. Drugs 2006; 66 (1): 31-49. Go to original source... Go to PubMed...
    406. Meneghini L, Koenen C, Weng W, Selam JL. PREDICTIVE 303 Study: Implementation and outcomes of a simplified self-titration dosing guideline for insulin detemir in patients with type 2 diabetes. Abstract Volume 43rd Annual Meeting, Amsterdam, 2007: S 98.
    407. Rosenstock J, et al. A randomized, 52-week, treat-totarget trial comparing insulin detemir with insulin glargin when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416. Go to original source... Go to PubMed...
    408. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine, 2008; 358: 2545-2559. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.